Attenuated Ehrlichia Mutant Strains for Protective Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Ehrlichia chaffeensis infections in humans and dogs are limited, with no effective vaccines available, and existing antibiotics provide only partial relief, while the pathogen's transmission via ticks and persistence in refrigerated blood pose additional challenges, especially for individuals with compromised immunity.
Innovation Solution
Development of attenuated mutant strains of Ehrlichia species, specifically targeting genes like Ech_0660, Ech_0379, and Ech_0230, which are used in immunogenic compositions to elicit immune responses and provide protective immunity against tick-transmitted Ehrlichia infections by administering these strains in a pharmaceutically acceptable carrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If live attenuated mutant strains are developed and used as vaccines, then protective immunity against Ehrlichia infections is achieved, but the complexity of vaccine development and strain characterization increases
Solution Approach 1:
The vaccine strategy segments the Ehrlichia pathogen by targeting specific genes (Ech_0660, Ech_0379, Ech_0230) for attenuation, creating multiple mutant strains with different genetic modifications. This segmentation allows systematic development of vaccine candidates by focusing on specific pathogen components rather than the entire organism.
Solution Approach 2:
The patent applies parameter changes by modifying specific genetic parameters of the Ehrlichia strain through targeted mutations. By changing the genetic makeup of the pathogen (attenuating specific genes while maintaining others), the vaccine strain achieves reduced virulence while preserving immunogenicity, resolving the contradiction between effectiveness and safety.
2Reliability
If multiple attenuated mutant strains are generated through targeted gene mutations, then protective immunity is enhanced, but the time and resources required for strain generation and characterization increase
Solution Approach 1:
The patent employs preliminary action by pre-characterizing the genetic functions of target genes (Ech_0660, Ech_0379, Ech_0230) before generating mutants. This preliminary understanding of gene function allows for more efficient strain generation, as the attenuation strategy is based on pre-identified critical genes, reducing trial-and-error in the mutation process.
Solution Approach 2:
The patent uses copying by creating multiple mutant strains that replicate the successful attenuation approach across different gene targets. Each mutant strain follows the same methodological framework (targeted gene disruption), allowing efficient generation of multiple vaccine candidates through standardized procedures rather than de novo development for each strain.
3Productivity
If existing antibiotics are used for treatment, then some clinical improvement is achieved, but complete cure rates remain limited and therapeutic options are insufficient
Solution Approach 1:
The patent extracts the therapeutic approach from the limited antibiotic class by developing a vaccine-based treatment that targets the root cause (Ehrlichia infection) rather than merely suppressing symptoms. The attenuated mutant strains serve as a new therapeutic modality that complements or replaces traditional antibiotics, providing more versatile treatment options.
Solution Approach 2:
The vaccine provides preliminary action by inducing protective immunity before the full-blown infection occurs, preventing the need for aggressive antibiotic treatment. This preventive approach reduces the burden on existing antibiotics and expands therapeutic versatility by offering a choice between prevention and treatment modalities.
Data Source
AI summary
Attenuated vaccines to protect vertebrate animals and people against tick-born rickettsial, Ehrlichia and Anaplasma species infections is disclosed. Also disclosed are methods to modify the organism to achieve the desired immunity through the modification of a novel genetic region involved in pathogenesis. These compounds represent a needed vaccine against an organism causing life-threatening febrile illness in humans and animals, and also represent the potential to develop new classes of drugs targeting the gene products of genes Ech_0379 and Ech_0230, and their homologs of other related rickettsial pathogens.